| __timestamp | Perrigo Company plc | Teva Pharmaceutical Industries Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 675200000 | 5078000000 |
| Thursday, January 1, 2015 | 771800000 | 4717000000 |
| Friday, January 1, 2016 | 1205500000 | 5096000000 |
| Sunday, January 1, 2017 | 1146500000 | 4986000000 |
| Monday, January 1, 2018 | 1125800000 | 4214000000 |
| Tuesday, January 1, 2019 | 1166100000 | 3806000000 |
| Wednesday, January 1, 2020 | 1175500000 | 3671000000 |
| Friday, January 1, 2021 | 1111400000 | 3528000000 |
| Saturday, January 1, 2022 | 1210100000 | 3445000000 |
| Sunday, January 1, 2023 | 1274600000 | 3498000000 |
| Monday, January 1, 2024 | 3702000000 |
Igniting the spark of knowledge
In the ever-evolving pharmaceutical industry, understanding the financial dynamics of major players is crucial. Over the past decade, Teva Pharmaceutical Industries Limited and Perrigo Company plc have showcased contrasting trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Teva's SG&A expenses have seen a significant decline of approximately 31%, dropping from 5.08 billion to 3.50 billion. This reduction reflects Teva's strategic cost-cutting measures amidst challenging market conditions. In contrast, Perrigo's SG&A expenses have steadily increased by about 89%, rising from 675 million to 1.27 billion. This growth indicates Perrigo's aggressive expansion and investment in operational capabilities. These financial trajectories highlight the distinct strategic paths taken by these pharmaceutical giants, offering valuable insights into their operational priorities and market positioning. As the industry continues to evolve, monitoring such financial indicators will be key to understanding future trends.
Operational Costs Compared: SG&A Analysis of Novartis AG and Perrigo Company plc
SG&A Efficiency Analysis: Comparing Vertex Pharmaceuticals Incorporated and Perrigo Company plc
Regeneron Pharmaceuticals, Inc. or Perrigo Company plc: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: argenx SE vs Perrigo Company plc
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and Bio-Techne Corporation
Teva Pharmaceutical Industries Limited vs Catalyst Pharmaceuticals, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Teva Pharmaceutical Industries Limited and Protagonist Therapeutics, Inc.
Comparing SG&A Expenses: Teva Pharmaceutical Industries Limited vs Bausch Health Companies Inc. Trends and Insights
Selling, General, and Administrative Costs: Teva Pharmaceutical Industries Limited vs Mesoblast Limited
Selling, General, and Administrative Costs: Teva Pharmaceutical Industries Limited vs MiMedx Group, Inc.
Breaking Down SG&A Expenses: Perrigo Company plc vs Protagonist Therapeutics, Inc.
Breaking Down SG&A Expenses: Perrigo Company plc vs Iovance Biotherapeutics, Inc.